CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 497 enrolled
Drug / intervention
Naproxen Sodium ER (BAYH6689)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00751400
NCT00751400Phase 3Completed
CompareCT.gov

An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting

Bayer·interventional·Posted Sep 12, 2008·Updated Aug 25, 2015

In Brief

A Phase 3 clinical trial evaluating Naproxen Sodium ER (BAYH6689) for Pain. Completed, enrolled 497 participants across 24 sites.

Detailed Summary

The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
CollaboratorsPegus Research, Inc.

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2008
Enrollment StartJul 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.8 years ago

Interventions

Naproxen Sodium ER (BAYH6689)drug

Consumer use of Extended Release Naproxen Sodium